Braidwell LP Buys 596,000 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Braidwell LP increased its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 36.3% during the third quarter, HoldingsChannel reports. The institutional investor owned 2,239,770 shares of the biopharmaceutical company’s stock after acquiring an additional 596,000 shares during the quarter. Braidwell LP’s holdings in Ocular Therapeutix were worth $19,486,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in OCUL. Vanguard Group Inc. raised its position in shares of Ocular Therapeutix by 41.4% in the first quarter. Vanguard Group Inc. now owns 7,235,131 shares of the biopharmaceutical company’s stock worth $65,840,000 after buying an additional 2,117,029 shares in the last quarter. American International Group Inc. raised its position in shares of Ocular Therapeutix by 43.4% in the first quarter. American International Group Inc. now owns 56,981 shares of the biopharmaceutical company’s stock worth $519,000 after buying an additional 17,251 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Ocular Therapeutix by 1,142.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 662,672 shares of the biopharmaceutical company’s stock worth $6,031,000 after buying an additional 609,328 shares in the last quarter. Bayesian Capital Management LP purchased a new stake in shares of Ocular Therapeutix in the first quarter worth $94,000. Finally, Cetera Investment Advisers raised its position in shares of Ocular Therapeutix by 6.5% in the first quarter. Cetera Investment Advisers now owns 725,990 shares of the biopharmaceutical company’s stock worth $6,607,000 after buying an additional 44,590 shares in the last quarter. Hedge funds and other institutional investors own 59.21% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Robert W. Baird lowered their price objective on Ocular Therapeutix from $18.00 to $17.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. HC Wainwright raised their price target on Ocular Therapeutix from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Friday, November 15th. Finally, Scotiabank assumed coverage on Ocular Therapeutix in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $22.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, Ocular Therapeutix presently has an average rating of “Moderate Buy” and a consensus price target of $16.71.

Ocular Therapeutix Trading Up 3.2 %

NASDAQ OCUL opened at $10.06 on Friday. The company has a market capitalization of $1.58 billion, a price-to-earnings ratio of -7.62 and a beta of 1.26. The stock’s 50-day simple moving average is $9.96 and its two-hundred day simple moving average is $8.22. The company has a quick ratio of 12.94, a current ratio of 13.01 and a debt-to-equity ratio of 0.19. Ocular Therapeutix, Inc. has a twelve month low of $2.16 and a twelve month high of $11.77.

Insider Transactions at Ocular Therapeutix

In other news, insider Jeffrey S. Heier sold 2,948 shares of Ocular Therapeutix stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $9.01, for a total value of $26,561.48. Following the transaction, the insider now owns 269,059 shares in the company, valued at approximately $2,424,221.59. The trade was a 1.08 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 3.50% of the company’s stock.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.